Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ATNM vs RAIN vs RNAC vs OESX vs IMVT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ATNM
Actinium Pharmaceuticals, Inc.

Biotechnology

HealthcareAMEX • US
Market Cap$41M
5Y Perf.+12.9%
RAIN
Rain Enhancement Technologies Holdco Inc

Renewable Utilities

UtilitiesNASDAQ • US
Market Cap$3M
5Y Perf.-66.0%
RNAC
Cartesian Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$229M
5Y Perf.-55.2%
OESX
Orion Energy Systems, Inc.

Electrical Equipment & Parts

IndustrialsNASDAQ • US
Market Cap$35M
5Y Perf.+25.1%
IMVT
Immunovant, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$5.88B
5Y Perf.+33.1%

ATNM vs RAIN vs RNAC vs OESX vs IMVT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ATNM logoATNM
RAIN logoRAIN
RNAC logoRNAC
OESX logoOESX
IMVT logoIMVT
IndustryBiotechnologyRenewable UtilitiesBiotechnologyElectrical Equipment & PartsBiotechnology
Market Cap$41M$3M$229M$35M$5.88B
Revenue (TTM)$90K$0.00$2M$81M$0.00
Net Income (TTM)$-23M$-6M$-152M$-5M$-464M
Gross Margin327.8%-6.3%29.9%
Operating Margin-283.5%-51.4%-4.3%
Total Debt$2M$4M$13M$10M$98K
Cash & Equiv.$48M$33K$125M$6M$714M

ATNM vs RAIN vs RNAC vs OESX vs IMVTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ATNM
RAIN
RNAC
OESX
IMVT
StockJan 25May 26Return
Actinium Pharmaceut… (ATNM)100112.9+12.9%
Rain Enhancement Te… (RAIN)10034.0-66.0%
Cartesian Therapeut… (RNAC)10044.8-55.2%
Orion Energy System… (OESX)100125.1+25.1%
Immunovant, Inc. (IMVT)100133.1+33.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: ATNM vs RAIN vs RNAC vs OESX vs IMVT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: OESX and IMVT are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Immunovant, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. ATNM also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
ATNM
Actinium Pharmaceuticals, Inc.
The Growth Leader

ATNM ranks third and is worth considering specifically for growth.

  • 49.4% revenue growth vs RAIN's -121.2%
Best for: growth
RAIN
Rain Enhancement Technologies Holdco Inc
The Utilities Pick

RAIN lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: utilities exposure
RNAC
Cartesian Therapeutics, Inc.
The Healthcare Pick

Among these 5 stocks, RNAC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
OESX
Orion Energy Systems, Inc.
The Income Pick

OESX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 1.03
  • Rev growth -12.0%, EPS growth 0.0%, 3Y rev CAGR -13.8%
  • Beta 1.03, current ratio 1.32x
  • Beta 1.03 vs RNAC's 2.04
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder

IMVT is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.

  • 190.9% 10Y total return vs OESX's -27.9%
  • Lower volatility, beta 1.36, Low D/E 0.0%, current ratio 11.16x
  • 3.2% margin vs ATNM's -260.8%
  • +102.4% vs RAIN's -81.4%
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthATNM logoATNM49.4% revenue growth vs RAIN's -121.2%
Quality / MarginsIMVT logoIMVT3.2% margin vs ATNM's -260.8%
Stability / SafetyOESX logoOESXBeta 1.03 vs RNAC's 2.04
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)IMVT logoIMVT+102.4% vs RAIN's -81.4%
Efficiency (ROA)OESX logoOESX-0.0% ROA vs RAIN's -298.9%

ATNM vs RAIN vs RNAC vs OESX vs IMVT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ATNMActinium Pharmaceuticals, Inc.
FY 2025
Other Revenue Member
100.0%$90,000
RAINRain Enhancement Technologies Holdco Inc

Segment breakdown not available.

RNACCartesian Therapeutics, Inc.
FY 2025
Operating Segment
100.0%$3M
OESXOrion Energy Systems, Inc.
FY 2024
Product
68.2%$54M
Service
31.8%$25M
IMVTImmunovant, Inc.

Segment breakdown not available.

ATNM vs RAIN vs RNAC vs OESX vs IMVT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLOESXLAGGINGRNAC

Income & Cash Flow (Last 12 Months)

OESX leads this category, winning 5 of 6 comparable metrics.

OESX and IMVT operate at a comparable scale, with $81M and $0 in trailing revenue. OESX is the more profitable business, keeping -5.6% of every revenue dollar as net income compared to ATNM's -260.8%. On growth, OESX holds the edge at +7.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricATNM logoATNMActinium Pharmace…RAIN logoRAINRain Enhancement …RNAC logoRNACCartesian Therape…OESX logoOESXOrion Energy Syst…IMVT logoIMVTImmunovant, Inc.
RevenueTrailing 12 months$90,000$0$2M$81M$0
EBITDAEarnings before interest/tax-$25M-$5M-$90M-$1M-$487M
Net IncomeAfter-tax profit-$23M-$6M-$152M-$5M-$464M
Free Cash FlowCash after capex-$23M-$4M-$77M$348M-$423M
Gross MarginGross profit ÷ Revenue+3.3%-6.3%+29.9%
Operating MarginEBIT ÷ Revenue-283.5%-51.4%-4.3%
Net MarginNet income ÷ Revenue-260.8%-85.5%-5.6%
FCF MarginFCF ÷ Revenue-255.4%-43.6%+4.3%
Rev. Growth (YoY)Latest quarter vs prior year-92.9%+7.7%
EPS Growth (YoY)Latest quarter vs prior year+64.7%-114.7%+109.6%+19.7%
OESX leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

OESX leads this category, winning 2 of 3 comparable metrics.
MetricATNM logoATNMActinium Pharmace…RAIN logoRAINRain Enhancement …RNAC logoRNACCartesian Therape…OESX logoOESXOrion Energy Syst…IMVT logoIMVTImmunovant, Inc.
Market CapShares × price$41M$3M$229M$35M$5.9B
Enterprise ValueMkt cap + debt − cash-$5M$6M$117M$39M$5.2B
Trailing P/EPrice ÷ TTM EPS-1.20x-0.55x-1.72x-2.74x-10.60x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue456.68x81.98x0.44x
Price / BookPrice ÷ Book value/share5.22x2.73x6.20x
Price / FCFMarket cap ÷ FCF71.04x
OESX leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

OESX leads this category, winning 4 of 8 comparable metrics.

OESX delivers a -0.0% return on equity — every $100 of shareholder capital generates $-0 in annual profit, vs $-2 for ATNM. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to OESX's 0.87x. On the Piotroski fundamental quality scale (0–9), OESX scores 4/9 vs RNAC's 1/9, reflecting mixed financial health.

MetricATNM logoATNMActinium Pharmace…RAIN logoRAINRain Enhancement …RNAC logoRNACCartesian Therape…OESX logoOESXOrion Energy Syst…IMVT logoIMVTImmunovant, Inc.
ROE (TTM)Return on equity-2.2%-0.0%-47.1%
ROA (TTM)Return on assets-43.4%-3.0%-45.1%-0.0%-44.1%
ROICReturn on invested capital-34.8%
ROCEReturn on capital employed-64.4%-25.0%-34.9%-66.1%
Piotroski ScoreFundamental quality 0–933142
Debt / EquityFinancial leverage0.22x0.87x0.00x
Net DebtTotal debt minus cash-$46M$3M-$112M$4M-$714M
Cash & Equiv.Liquid assets$48M$32,604$125M$6M$714M
Total DebtShort + long-term debt$2M$4M$13M$10M$98,000
Interest CoverageEBIT ÷ Interest expense-148.90x-3.29x
OESX leads this category, winning 4 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

IMVT leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in IMVT five years ago would be worth $18,445 today (with dividends reinvested), compared to $1,022 for RNAC. Over the past 12 months, IMVT leads with a +102.4% total return vs RAIN's -81.4%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.4% vs ATNM's -46.7% — a key indicator of consistent wealth creation.

MetricATNM logoATNMActinium Pharmace…RAIN logoRAINRain Enhancement …RNAC logoRNACCartesian Therape…OESX logoOESXOrion Energy Syst…IMVT logoIMVTImmunovant, Inc.
YTD ReturnYear-to-date-4.4%-74.6%+28.0%-33.8%+11.7%
1-Year ReturnPast 12 months-8.4%-81.4%-17.0%+38.4%+102.4%
3-Year ReturnCumulative with dividends-84.9%-82.6%-75.8%-34.6%+49.8%
5-Year ReturnCumulative with dividends-82.1%-82.6%-89.8%-82.3%+84.4%
10-Year ReturnCumulative with dividends-97.5%-82.6%-97.9%-27.9%+190.9%
CAGR (3Y)Annualised 3-year return-46.7%-44.2%-37.7%-13.2%+14.4%
IMVT leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — OESX and IMVT each lead in 1 of 2 comparable metrics.

OESX is the less volatile stock with a 1.03 beta — it tends to amplify market swings less than RNAC's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 96.2% from its 52-week high vs RAIN's 13.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricATNM logoATNMActinium Pharmace…RAIN logoRAINRain Enhancement …RNAC logoRNACCartesian Therape…OESX logoOESXOrion Energy Syst…IMVT logoIMVTImmunovant, Inc.
Beta (5Y)Sensitivity to S&P 5001.32x1.20x2.04x1.03x1.36x
52-Week HighHighest price in past year$1.95$9.58$15.57$18.64$30.09
52-Week LowLowest price in past year$0.95$1.27$5.60$5.50$13.36
% of 52W HighCurrent price vs 52-week peak+67.2%+13.3%+55.6%+53.0%+96.2%
RSI (14)Momentum oscillator 0–10051.226.365.845.750.6
Avg Volume (50D)Average daily shares traded185K20K223K39K1.4M
Evenly matched — OESX and IMVT each lead in 1 of 2 comparable metrics.

Analyst Outlook

OESX leads this category, winning 1 of 1 comparable metric.

Analyst consensus: RNAC as "Buy", IMVT as "Buy". Consensus price targets imply 85.0% upside for RNAC (target: $16) vs 57.2% for IMVT (target: $46).

MetricATNM logoATNMActinium Pharmace…RAIN logoRAINRain Enhancement …RNAC logoRNACCartesian Therape…OESX logoOESXOrion Energy Syst…IMVT logoIMVTImmunovant, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$16.00$45.50
# AnalystsCovering analysts1023
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises01
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+0.0%0.0%
OESX leads this category, winning 1 of 1 comparable metric.
Key Takeaway

OESX leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). IMVT leads in 1 (Total Returns). 1 tied.

Best OverallOrion Energy Systems, Inc. (OESX)Leads 4 of 6 categories
Loading custom metrics...

ATNM vs RAIN vs RNAC vs OESX vs IMVT: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is ATNM or RAIN or RNAC or OESX or IMVT a better buy right now?

For growth investors, Orion Energy Systems, Inc.

(OESX) is the stronger pick with -12. 0% revenue growth year-over-year, versus -92. 8% for Cartesian Therapeutics, Inc. (RNAC). Analysts rate Cartesian Therapeutics, Inc. (RNAC) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — ATNM or RAIN or RNAC or OESX or IMVT?

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +84. 4%, compared to -89. 8% for Cartesian Therapeutics, Inc. (RNAC). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus RNAC's -97. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — ATNM or RAIN or RNAC or OESX or IMVT?

By beta (market sensitivity over 5 years), Orion Energy Systems, Inc.

(OESX) is the lower-risk stock at 1. 03β versus Cartesian Therapeutics, Inc. 's 2. 04β — meaning RNAC is approximately 97% more volatile than OESX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 87% for Orion Energy Systems, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — ATNM or RAIN or RNAC or OESX or IMVT?

By revenue growth (latest reported year), Orion Energy Systems, Inc.

(OESX) is pulling ahead at -12. 0% versus -92. 8% for Cartesian Therapeutics, Inc. (RNAC). On earnings-per-share growth, the picture is similar: Actinium Pharmaceuticals, Inc. grew EPS 14. 2% year-over-year, compared to -34. 9% for Rain Enhancement Technologies Holdco Inc. Over a 3-year CAGR, OESX leads at -13. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — ATNM or RAIN or RNAC or OESX or IMVT?

Rain Enhancement Technologies Holdco Inc (RAIN) is the more profitable company, earning 0.

0% net margin versus -376. 5% for Actinium Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RAIN leads at 0. 0% versus -402. 7% for ATNM. At the gross margin level — before operating expenses — ATNM leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — ATNM or RAIN or RNAC or OESX or IMVT?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is ATNM or RAIN or RNAC or OESX or IMVT better for a retirement portfolio?

For long-horizon retirement investors, Orion Energy Systems, Inc.

(OESX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03)). Cartesian Therapeutics, Inc. (RNAC) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OESX: -27. 9%, RNAC: -97. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between ATNM and RAIN and RNAC and OESX and IMVT?

These companies operate in different sectors (ATNM (Healthcare) and RAIN (Utilities) and RNAC (Healthcare) and OESX (Industrials) and IMVT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ATNM

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 196%
Run This Screen
Stocks Like

RAIN

Quality Business

  • Sector: Utilities
  • Market Cap > $100B
Run This Screen
Stocks Like

RNAC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

OESX

Quality Business

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 17%
Run This Screen
Stocks Like

IMVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.